Reverse phase-liquid chromatography assisted protocol for simultaneous determination of lamivudine and tenofovir disoproxil fumarate in combined medication used to control HIV infection: an investigative approach

Future Journal of Pharmaceutical Sciences

Table 2 Investigation of accuracy study

Initial amount [μg/mL]	Amount added [μg/mL]	Amount found [μg/mL]		% Recovery		% RSD
Initial amount [μg/mL]	Amount added [μg/mL]	LVD	TDF	LVD	TDF	LVD	TDF
Level of recovery study 80%
20	16	36.10	35.90	100.62	99.66	0.49	0.44
20	16	35.95	36.04	99.68	100.51
20	16	35.98	35.99	99.87	99.88
Mean ± SD 100.05 ± 0.49100.01 ± 0.44
Level of recovery study 100%
20	20	39.87	39.77	99.38	99.28	0.72	0.83
20	20	39.96	40.00	99.80	100.00
20	20	39.68	39.56	98.40	98.35
Mean ± SD 99.19 ± 0.71 99.21 ± 0.82
Level of recovery study 120%
20	24	44.05	43.95	100.20	99.80	0.20	0.10
20	24	43.95	44.00	99.79	100.00
20	24	44.00	43.95	100.00	99.85
Mean ± SD 99.99 ± 0.20 99.88 ± 0.10